Header Logo

Connection

Lesley Scott to Humans

This is a "connection" page, showing publications Lesley Scott has written about Humans.
Connection Strength

1,834
  1. Track Omicron's spread with molecular data. Science. 2021 Dec 17; 374(6574):1454-1455.
    View in: PubMed
    Score: 0,059
  2. Rifampicin-resistant TB: discordance between Xpert® MTB/RIF and MTBDRplus results. Int J Tuberc Lung Dis. 2021 10 01; 25(10):832-838.
    View in: PubMed
    Score: 0,058
  3. Exploring a collaborative approach to the involvement of patients, carers and the public in the initial education and training of healthcare professionals: A qualitative study of patient experiences. Health Expect. 2021 12; 24(6):1988-1994.
    View in: PubMed
    Score: 0,058
  4. Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting. J Mol Diagn. 2020 10; 22(10):1225-1237.
    View in: PubMed
    Score: 0,054
  5. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. Drugs. 2020 Jan; 80(1):61-72.
    View in: PubMed
    Score: 0,052
  6. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
    View in: PubMed
    Score: 0,048
  7. Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
    View in: PubMed
    Score: 0,044
  8. Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa. J Clin Microbiol. 2017 08; 55(8):2491-2501.
    View in: PubMed
    Score: 0,043
  9. Choosing a new CD4 technology: Can statistical method comparison tools influence the decision? Cytometry B Clin Cytom. 2017 11; 92(6):465-475.
    View in: PubMed
    Score: 0,043
  10. Diagnosis of opportunistic infections: HIV co-infections - tuberculosis. Curr Opin HIV AIDS. 2017 03; 12(2):129-138.
    View in: PubMed
    Score: 0,042
  11. Alitretinoin: A Review in Severe Chronic Hand Eczema. Drugs. 2016 Sep; 76(13):1271-1279.
    View in: PubMed
    Score: 0,041
  12. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. Drugs. 2016 Sep; 76(13):1301-1312.
    View in: PubMed
    Score: 0,041
  13. A meta-analysis of the performance of the Pima™ CD4 for point of care testing. BMC Med. 2015 Jul 25; 13:168.
    View in: PubMed
    Score: 0,038
  14. Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. J Clin Microbiol. 2015 May; 53(5):1616-21.
    View in: PubMed
    Score: 0,037
  15. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015 Jan; 75(1):91-100.
    View in: PubMed
    Score: 0,037
  16. Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa. J Clin Microbiol. 2014 Jul; 52(7):2493-9.
    View in: PubMed
    Score: 0,035
  17. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. J Clin Microbiol. 2014 Jun; 52(6):1818-23.
    View in: PubMed
    Score: 0,035
  18. A laboratorian's experience of implementing multiple point-of-care testing in HIV antiretroviral treatment clinics in South Africa. S Afr Med J. 2013 Dec; 103(12):883-4.
    View in: PubMed
    Score: 0,034
  19. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. Clin Drug Investig. 2012 Oct 01; 32(10):715-22.
    View in: PubMed
    Score: 0,031
  20. Use of a prequalification panel for rapid scale-up of high-throughput HIV viral load testing. J Clin Microbiol. 2012 Dec; 50(12):4083-6.
    View in: PubMed
    Score: 0,031
  21. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
    View in: PubMed
    Score: 0,029
  22. Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction. J Virol Methods. 2011 Mar; 172(1-2):78-80.
    View in: PubMed
    Score: 0,028
  23. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection. Paediatr Drugs. 2010 Apr 01; 12(2):123-31.
    View in: PubMed
    Score: 0,026
  24. Raltegravir: in treatment-naive patients with HIV-1 infection. Drugs. 2010 Mar 26; 70(5):631-42.
    View in: PubMed
    Score: 0,026
  25. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol. 2009 Oct; 47(10):3400-2.
    View in: PubMed
    Score: 0,025
  26. Ultra-high-throughput, automated nucleic acid detection of human immunodeficiency virus (HIV) for infant infection diagnosis using the Gen-Probe Aptima HIV-1 screening assay. J Clin Microbiol. 2009 Aug; 47(8):2465-9.
    View in: PubMed
    Score: 0,025
  27. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009 Jul; 47(7):2209-17.
    View in: PubMed
    Score: 0,025
  28. Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005; 65(16):2309-36.
    View in: PubMed
    Score: 0,018
  29. Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
    View in: PubMed
    Score: 0,018
  30. Translating the consent form is the tip of the iceberg: using cognitive interviews to assess the barriers to informed consent in South African health facilities. Sex Reprod Health Matters. 2023 Dec; 31(4):2302553.
    View in: PubMed
    Score: 0,017
  31. Tuberculosis testing patterns in South Africa to identify groups that would benefit from increased investigation. Sci Rep. 2023 11 27; 13(1):20875.
    View in: PubMed
    Score: 0,017
  32. Multiple method comparison: statistical model using percentage similarity. Cytometry B Clin Cytom. 2003 Jul; 54(1):46-53.
    View in: PubMed
    Score: 0,016
  33. Cross-municipality migration and spread of tuberculosis in South Africa. Sci Rep. 2023 02 15; 13(1):2674.
    View in: PubMed
    Score: 0,016
  34. Co-testing a single sputum specimen for TB and SARS-CoV-2. Int J Tuberc Lung Dis. 2023 02 01; 27(2):146-147.
    View in: PubMed
    Score: 0,016
  35. Emtricitabine: an antiretroviral agent for HIV infection. Drugs. 2003; 63(22):2413-24; discussion 2425-6.
    View in: PubMed
    Score: 0,016
  36. Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis?and Resistance to Rifampicin and Isoniazid. J Mol Diagn. 2023 01; 25(1):46-56.
    View in: PubMed
    Score: 0,016
  37. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022 09; 28(9):1785-1790.
    View in: PubMed
    Score: 0,015
  38. Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One. 2022; 17(2):e0262442.
    View in: PubMed
    Score: 0,015
  39. Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. J Virol Methods. 2022 04; 302:114471.
    View in: PubMed
    Score: 0,015
  40. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 03; 603(7902):679-686.
    View in: PubMed
    Score: 0,015
  41. Antigen-Based Point of Care Testing (POCT) for Diagnosing SARS-CoV-2: Assessing Performance. Methods Mol Biol. 2022; 2452:45-62.
    View in: PubMed
    Score: 0,015
  42. Guidance for SARS-CoV-2 RNA-Based Molecular Assay Analytical Performance Evaluations. Methods Mol Biol. 2022; 2511:99-115.
    View in: PubMed
    Score: 0,015
  43. Evaluation Protocol for SARS-CoV-2 Serological Assays. Methods Mol Biol. 2022; 2511:307-319.
    View in: PubMed
    Score: 0,015
  44. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022 02; 22(2):242-249.
    View in: PubMed
    Score: 0,015
  45. Diagnostic performance of the Abbott RealTime MTB assay for tuberculosis diagnosis in people living with HIV. Sci Rep. 2021 09 29; 11(1):19271.
    View in: PubMed
    Score: 0,015
  46. Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response. J Immunol Methods. 2021 09; 496:113096.
    View in: PubMed
    Score: 0,014
  47. Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa. PLoS One. 2021; 16(6):e0252317.
    View in: PubMed
    Score: 0,014
  48. Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. J Clin Microbiol. 2021 02 18; 59(3).
    View in: PubMed
    Score: 0,014
  49. Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa. Int J Tuberc Lung Dis. 2021 02 01; 25(2):134-141.
    View in: PubMed
    Score: 0,014
  50. Delavirdine: a review of its use in HIV infection. Drugs. 2000 Dec; 60(6):1411-44.
    View in: PubMed
    Score: 0,014
  51. The role of serological testing in the SARS-CoV-2 outbreak. S Afr Med J. 2020 07 17; 110(9):842-845.
    View in: PubMed
    Score: 0,013
  52. Accurate HIV viral load measurement in primary health care settings using the cobas® plasma separation card. PLoS One. 2020; 15(5):e0232122.
    View in: PubMed
    Score: 0,013
  53. Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa. BMC Infect Dis. 2020 May 04; 20(1):320.
    View in: PubMed
    Score: 0,013
  54. Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020 05 01; 75(5):1123-1129.
    View in: PubMed
    Score: 0,013
  55. Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. Clin Infect Dis. 2020 03 03; 70(6):1014-1020.
    View in: PubMed
    Score: 0,013
  56. Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. J Infect Dis. 2019 10 08; 220(220 Suppl 3):S99-S107.
    View in: PubMed
    Score: 0,013
  57. Performance of Cepheid Xpert HIV-1 viral load plasma assay to accurately detect treatment failure. AIDS. 2019 10 01; 33(12):1881-1889.
    View in: PubMed
    Score: 0,013
  58. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018 10 01; 73(10):2667-2674.
    View in: PubMed
    Score: 0,012
  59. Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method. J Clin Microbiol. 2018 09; 56(9).
    View in: PubMed
    Score: 0,012
  60. Comparison of IgA-alpha1-antitrypsin levels in rheumatoid arthritis and seronegative oligoarthritis: complex formation is not associated with inflammation per se. Br J Rheumatol. 1998 Apr; 37(4):398-404.
    View in: PubMed
    Score: 0,011
  61. HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. PLoS One. 2017; 12(12):e0188606.
    View in: PubMed
    Score: 0,011
  62. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018 01; 18(1):76-84.
    View in: PubMed
    Score: 0,011
  63. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508.
    View in: PubMed
    Score: 0,011
  64. Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. Microbiol Spectr. 2017 01; 5(1).
    View in: PubMed
    Score: 0,010
  65. Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay. PLoS One. 2016; 11(12):e0168244.
    View in: PubMed
    Score: 0,010
  66. Human Immunodeficiency Virus (HIV)-Infected Patients Accept Finger Stick Blood Collection for Point-Of-Care CD4 Testing. PLoS One. 2016; 11(8):e0161891.
    View in: PubMed
    Score: 0,010
  67. A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC Infect Dis. 2016 06 10; 16:269.
    View in: PubMed
    Score: 0,010
  68. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia. 2016 06; 30(6):1273-81.
    View in: PubMed
    Score: 0,010
  69. Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
    View in: PubMed
    Score: 0,010
  70. A High Burden Human Immunodeficiency Virus and Tuberculosis Resource Limited Setting, Gains from Including Xpert MTB/RIF in the Diagnostic Algorithm of Fluid Specimens Submitted for Exclusion of Lymphoma by Immunophenotypic Analysis. PLoS One. 2015; 10(8):e0134404.
    View in: PubMed
    Score: 0,010
  71. The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
    View in: PubMed
    Score: 0,009
  72. The Video Interaction Guidance approach applied to teaching communication skills in dentistry. Eur J Dent Educ. 2016 May; 20(2):94-101.
    View in: PubMed
    Score: 0,009
  73. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia. 2015 Jul; 29(7):1514-23.
    View in: PubMed
    Score: 0,009
  74. Applying the Verona coding definitions of emotional sequences (VR-CoDES) in the dental context involving patients with complex communication needs: An exploratory study. Patient Educ Couns. 2014 Nov; 97(2):180-7.
    View in: PubMed
    Score: 0,009
  75. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
    View in: PubMed
    Score: 0,009
  76. Successes, challenges and lessons from a novel deployment of Xpert(®) MTB/RIF at a major South African public event [Short Communication]. Int J Tuberc Lung Dis. 2014 Apr; 18(4):438-40.
    View in: PubMed
    Score: 0,009
  77. Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment initiation and monitoring from multiple or single fingersticks. PLoS One. 2013; 8(12):e85265.
    View in: PubMed
    Score: 0,009
  78. Prevalence, risk factors and risk perception of tuberculosis infection among medical students and healthcare workers in Johannesburg, South Africa. S Afr Med J. 2013 Sep 30; 103(11):853-7.
    View in: PubMed
    Score: 0,008
  79. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,008
  80. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. Eur J Clin Microbiol Infect Dis. 2013 Nov; 32(11):1409-15.
    View in: PubMed
    Score: 0,008
  81. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013 Mar; 17(3):368-72.
    View in: PubMed
    Score: 0,008
  82. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
    View in: PubMed
    Score: 0,008
  83. Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations. PLoS One. 2012; 7(8):e41166.
    View in: PubMed
    Score: 0,008
  84. False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis. 2012 Feb; 16(2):206-8.
    View in: PubMed
    Score: 0,007
  85. Acute post-streptococcal glomerulonephritis in the Northern Territory of Australia: a review of 16 years data and comparison with the literature. Am J Trop Med Hyg. 2011 Oct; 85(4):703-10.
    View in: PubMed
    Score: 0,007
  86. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
    View in: PubMed
    Score: 0,007
  87. Should South Africa be performing nucleic acid testing on HIV enzyme-linked immunosorbent assay-negative samples? J Clin Microbiol. 2010 Sep; 48(9):3407-9.
    View in: PubMed
    Score: 0,007
  88. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis. 2010 Apr 15; 201 Suppl 1:S16-26.
    View in: PubMed
    Score: 0,007
  89. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009 Jul; 83(1):90-3.
    View in: PubMed
    Score: 0,006
  90. HIV prevalence among medical students in Johannesburg, South Africa. S Afr Med J. 2009 Feb; 99(2):72.
    View in: PubMed
    Score: 0,006
  91. Evaluating new CD4 enumeration technologies for resource-constrained countries. Nat Rev Microbiol. 2008 Nov; 6(11 Suppl):S29-38.
    View in: PubMed
    Score: 0,006
  92. Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: association with HIV seropositivity. Sex Transm Infect. 2008 Oct; 84(5):352-5.
    View in: PubMed
    Score: 0,006
  93. Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S40-51.
    View in: PubMed
    Score: 0,006
  94. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
    View in: PubMed
    Score: 0,006
  95. Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR. Mol Biotechnol. 2006 Feb; 32(2):101-10.
    View in: PubMed
    Score: 0,005
  96. HIV/AIDS prevalence testing--merits, methodology and outcomes of a survey conducted at a large mining organisation in South Africa. S Afr Med J. 2006 Feb; 96(2):134-9.
    View in: PubMed
    Score: 0,005
  97. Tuberculosis in east timorese refugees: implications for health care needs in East Timor. Int J Tuberc Lung Dis. 2002 Nov; 6(11):980-7.
    View in: PubMed
    Score: 0,004
  98. CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration. Cytometry. 2002 Apr 15; 50(2):69-77.
    View in: PubMed
    Score: 0,004
  99. Affordable CD4+ T cell counts by flow cytometry. II. The use of fixed whole blood in resource-poor settings. J Immunol Methods. 2001 Nov 01; 257(1-2):145-54.
    View in: PubMed
    Score: 0,004
  100. Microvolume fluorimetry for the determination of absolute CD4 and CD8 lymphocyte counts in patients with HIV: a comparative evaluation. Clin Lab Haematol. 1999 Dec; 21(6):391-5.
    View in: PubMed
    Score: 0,003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.